The antiinflammatory effects of aprotinin in patients undergoing cardiac surgery with cardiopulmonary bypass

Alfred H. Stammers, Suzanne Huffman, Anselmo Alonso, Lance W. Fristoe, Gary Hill, Dana Casebeer, Robert P. Diego, Zuorui Song

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


Aprotinin has been shown to effectively attenuate cardiopulmonary bypass (CPB) induced coagulopathies. Because aprotinin is a serine protease inhibitor, it may exert additional properties that reduce the risks associated with extracorporeal flow. The purpose of this study was to prospectively evaluate the antiinflammatory effects of aprotinin with specific emphasis on pulmonary function. After Institutional Review Board approval, 20 patients undergoing first time coronary artery bypass grafting were randomly assigned to receive either a full dose regimen of aprotinin (APR, n=8), or volumetric equal control (CTR, n=12). Biological markers of inflammation and coagulation were measured at 3 time periods: immediately prior to drug administration, at chest closure, and at 24 hours post cardiotomy, and included total complement, polymorphonuclear neutrophil (PMN) elastase, Factor XII, protein C, protein S, fibrin split products (FSP), D- dimers. Pulmonary function was assessed throughout intensive care unit (ICU) stay. There were no differences observed between groups in either preoperative, surgical, anesthesia or perfusion parameters. Twenty-four hour chest tube drainage in the APR group was significantly less than that observed in CTR patients (435.1±169.6 vs. 944.0±585.1, p<.02). Patients receiving aprotinin received significantly lower transfusions of red blood cells, platelets, and fresh frozen plasma. Upon entry into the ICU the CTR group had significantly higher mean airway pressures (8.3±1.5 vs. 10.8±2.9 cm H2O, p<.03), higher PaCO2 levels (37.1±4.8 vs. 43.3±7.1 mmHg, p<.04), and higher FIO2 settings (0.63±0.18 vs. 0.75±0.20, p=.16). Postoperative FSP and D-dimers were significantly lower in the APR treated patients. In conclusion, the use of aprotinin resulted in significant improvements to postoperative patient outcomes as assessed by transfusion requirements, blood loss, coagulation markers and pulmonary function.

Original languageEnglish (US)
Pages (from-to)114-122
Number of pages9
JournalJournal of Extra-Corporeal Technology
Issue number3
StatePublished - Sep 1997


  • Aprotinin
  • Cardiopulmonary bypass
  • Coagulation
  • Inflammation
  • Serine protease inhibition

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Health Professions (miscellaneous)
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'The antiinflammatory effects of aprotinin in patients undergoing cardiac surgery with cardiopulmonary bypass'. Together they form a unique fingerprint.

Cite this